Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Despite huge efforts made in academic and pharmaceutical worldwide research, current anticancer therapies achieve effective treatment in a limited number of neoplasia cases only. Oncology terms such as big killers - to identify tumours with yet a high mortality rate - or undruggable cancer targets, and chemoresistance, represent the current therapeutic debacle of cancer treatments. In addition, metastases, tumour microenvironments, tumour heterogeneity, metabolic adaptations, and immunotherapy resistance are essential features controlling tumour response to therapies, but still, lack effective therapeutics or modulators. In this scenario, where the pharmaceutical productivity and drug efficacy in oncology seem to have reached a plateau, the so-called drug repurposing - i.e. the use of old drugs, already in clinical use, for a different therapeutic indication - is an appealing strategy to improve cancer therapy. Opportunities for drug repurposing are often based on occasional observations or on time-consuming pre-clinical drug screenings that are often not hypothesis-driven. In contrast, in-silico drug repurposing is an emerging, hypothesis-driven approach that takes advantage of the use of big-data. Indeed, the extensive use of -omics technologies, improved data storage, data meaning, machine learning algorithms, and computational modeling all offer unprecedented knowledge of the biological mechanisms of cancers and drugs' modes of action, providing extensive availability for both disease-related data and drugs-related data. This offers the opportunity to generate, with time and cost-effective approaches, computational drug networks to predict, in-silico, the efficacy of approved drugs against relevant cancer targets, as well as to select better responder patients or disease' biomarkers. Here, we will review selected disease-related data together with computational tools to be exploited for the in-silico repurposing of drugs against validated targets in cancer therapies, focusing on the oncogenic signaling pathways activation in cancer. We will discuss how in-silico drug repurposing has the promise to shortly improve our arsenal of anticancer drugs and, likely, overcome certain limitations of modern cancer therapies against old and new therapeutic targets in oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
Lipton, Z. C. (2018) · Queue · doi:10.1145/3236386.3241340 · Cited by 5,427
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Research works printed but not linked: 156
- Booth, 2004, Prospects for productivity, Nat. Rev. Drug Discov., 3, 451, 10.1038/nrd1384 · DOI · Paper page
- Shih, 2018, Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications, Nat. Rev. Drug Discov., 17, 19, 10.1038/nrd.2017.194 · DOI
- Patel, 2017, Phase 2 to phase 3 clinical trial transitions: reasons for success and failure in immunologic diseases, J. Allergy Clin. Immunol., 140, 685, 10.1016/j.jaci.2017.04.029 · DOI
- Mohs, 2017, Drug discovery and development: role of basic biological research, Alzheimers Dement. N. Y., 3, 651, 10.1016/j.trci.2017.10.005 · DOI · Paper page
- Glode, 2017, Rising cost of Cancer pharmaceuticals: cost issues and interventions to control costs, Pharmacotherapy, 37, 85, 10.1002/phar.1867 · DOI
- Malik, 2009, Controlling the cost of innovative cancer therapeutics, Nat. Rev. Clin. Oncol., 6, 550, 10.1038/nrclinonc.2009.113 · DOI
- Papapetropoulos, 2018, Inventing new therapies without reinventing the wheel: the power of drug repurposing, Br. J. Pharmacol., 175, 165, 10.1111/bph.14081 · DOI
- Shaughnessy, 2011, Old drugs, new tricks, BMJ, 342, d741, 10.1136/bmj.d741 · DOI
- Kimmelman, 2018, The paradox of precision medicine, Nat. Rev. Clin. Oncol., 15, 341, 10.1038/s41571-018-0016-0 · DOI
- Cha, 2018, Drug repurposing from the perspective of pharmaceutical companies, Br. J. Pharmacol., 175, 168, 10.1111/bph.13798 · DOI · Paper page
- Wilkinson, 2015, In vitro screening for drug repositioning, J. Biomol. Screen., 20, 167, 10.1177/1087057114563024 · DOI
- Iljin, 2009, High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth, Clin. Cancer Res., 15, 6070, 10.1158/1078-0432.CCR-09-1035 · DOI · Paper page
- Chateauvieux, 2010, Molecular and therapeutic potential and toxicity of valproic acid, J. Biomed. Biotechnol., 2010, 10.1155/2010/479364 · DOI · Paper page
- Shim, 2014, Recent advances in drug repositioning for the discovery of new anticancer drugs, Int. J. Biol. Sci., 10, 654, 10.7150/ijbs.9224 · DOI · Paper page
- Calvo, 2016, Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies, Am. Soc. Clin. Oncol. Educ. Book, 35, e175, 10.1200/EDBK_159061 · DOI
- Gillies, 2018, Eco-evolutionary causes and consequences of temporal changes in intratumoural blood flow, Nat. Rev. Cancer, 18, 576, 10.1038/s41568-018-0030-7 · DOI · Paper page
- Menden, 2019, Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen, Nat. Commun., 10, 2674, 10.1038/s41467-019-09799-2 · DOI · Paper page
- Huang, 2014, Systematic prediction of drug combinations based on clinical side-effects, Sci. Rep., 4, 7160, 10.1038/srep07160 · DOI · Paper page
- Pemovska, 2013, Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia, Cancer Discov., 3, 1416, 10.1158/2159-8290.CD-13-0350 · doi:10.1158/2159-8290.cd-13-0350
- Shaked, 2016, Metabolic network prediction of drug side effects, Cell Syst., 2, 209, 10.1016/j.cels.2016.03.001 · DOI
- von Eichborn, 2011, PROMISCUOUS: a database for network-based drug-repositioning, Nucleic Acids Res., 39, D1060, 10.1093/nar/gkq1037 · DOI · Paper page
- Yang, 2011, Systematic drug repositioning based on clinical side-effects, PLoS One, 6, 10.1371/journal.pone.0028025 · DOI · Paper page
- Ye, 2014, Construction of drug network based on side effects and its application for drug repositioning, PLoS One, 9, 10.1371/journal.pone.0087864 · DOI
- Camacho, 2018, Next-generation machine learning for biological networks, Cell, 173, 1581, 10.1016/j.cell.2018.05.015 · DOI · Paper page
- Gottlieb, 2011, PREDICT: a method for inferring novel drug indications with application to personalized medicine, Mol. Syst. Biol., 7, 496, 10.1038/msb.2011.26 · DOI · Paper page
- Mottini, 2019, Predictive signatures inform the effective repurposing of Decitabine to treat K-RAS-dependent Pancreatic Ductal Adenocarcinoma, Cancer Res., 10.1158/0008-5472.CAN-19-0187 · DOI
- Karczewski, 2012, Chapter 7: pharmacogenomics, PLoS Comput. Biol., 8, 10.1371/journal.pcbi.1002817 · DOI · Paper page
- Oprea, 2015, Computational and practical aspects of drug repositioning, Assay Drug Dev. Technol., 13, 299, 10.1089/adt.2015.29011.tiodrrr · DOI · Paper page
- Wu, 2016, SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug–target interactions and drug repositioning, Brief. Bioinformatics, 18, 333
- Gaulton, 2017, The ChEMBL database in 2017, Nucleic Acids Res., 45, D945, 10.1093/nar/gkw1074 · DOI · Paper page
- Yap, 2011, PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints, J. Comput. Chem., 32, 1466, 10.1002/jcc.21707 · DOI · Paper page
- Gong, 2013, ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method, Bioinformatics, 29, 1827, 10.1093/bioinformatics/btt270 · DOI · Paper page
- Wang, 2015, Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation, Nat. Chem., 7, 968, 10.1038/nchem.2381 · DOI · Paper page
- Liang, 2017, LRSSL: predict and interpret drug–disease associations based on data integration using sparse subspace learning, Bioinformatics, 33, 1187, 10.1093/bioinformatics/btw770 · DOI · Paper page
- Vidović, 2014, Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action, Front. Genet., 5, 342
- Cheng, 2016, Systematic quality control analysis of LINCS data, CPT Pharmacometrics Syst. Pharmacol., 5, 588, 10.1002/psp4.12107 · DOI
- Huang, 2018, Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma, Sci. Transl. Med., 10, 10.1126/scitranslmed.aat0150 · DOI
- Chen, 2016, A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer, BMC Med. Genomics, 9, 51, 10.1186/s12920-016-0212-7 · DOI
- Iorio, 2010, Discovery of drug mode of action and drug repositioning from transcriptional responses, Proc. Natl. Acad. Sci., 107, 14621, 10.1073/pnas.1000138107 · DOI · Paper page
- Carrella, 2014, Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis, Bioinformatics, 30, 1787, 10.1093/bioinformatics/btu058 · DOI
- Carrella, 2016, Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds, Oncotarget, 7, 58743, 10.18632/oncotarget.11318 · DOI · Paper page
- Napolitano, 2016, Drug-set enrichment analysis: a novel tool to investigate drug mode of action, Bioinformatics, 32, 235, 10.1093/bioinformatics/btv536 · DOI · Paper page
- Napolitano, 2017, gene2drug: a computational tool for pathway-based rational drug repositioning, Bioinformatics, 34, 1498, 10.1093/bioinformatics/btx800 · DOI · Paper page
- Whirl-Carrillo, 2012, Pharmacogenomics knowledge for personalized medicine, Clin. Pharmacol. Ther., 92, 414, 10.1038/clpt.2012.96 · DOI · Paper page
- Igarashi, 2015, Open TG-GATEs: a large-scale toxicogenomics database, Nucleic Acids Res., 43, D921, 10.1093/nar/gku955 · DOI · Paper page
- Sirota, 2011, Discovery and preclinical validation of drug indications using compendia of public gene expression data, Sci. Transl. Med., 3, 10.1126/scitranslmed.3001318 · DOI · Paper page
- Dudley, 2011, Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease, Sci. Transl. Med., 3, 10.1126/scitranslmed.3002648 · DOI · Paper page
- Kim, 2019, Computational drug repositioning for gastric Cancer using reversal gene expression profiles, Sci. Rep., 9, 2660, 10.1038/s41598-019-39228-9 · DOI
- Yang, 2014, Drug-disease association and drug-repositioning predictions in complex diseases using causal inference-probabilistic matrix factorization, J. Chem. Inf. Model., 54, 2562, 10.1021/ci500340n · DOI
- Li, 2013, Pathway-based drug repositioning using causal inference, BMC Bioinformatics, 14, S3, 10.1186/1471-2105-14-S16-S3 · DOI
- Zhang, 2014, Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity, AMIA Annu. Symp. Proc., 2014, 1258
- Chen, 2012, Predicting anatomical therapeutic chemical (ATC) classification of drugs by integrating chemical-Chemical interactions and similarities, PLoS One, 7
- Wang, 2013, Network predicting drug’s anatomical therapeutic chemical code, Bioinformatics, 29, 1317, 10.1093/bioinformatics/btt158 · DOI
- Pagliarini, 2016, In silico modeling of liver metabolism in a human disease reveals a key enzyme for histidine and histamine homeostasis, Cell Rep., 15, 2292, 10.1016/j.celrep.2016.05.014 · DOI
- Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 · DOI · Paper page
- Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
- N. Cancer Genome Atlas, 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412 · DOI · Paper page
- N. Cancer Genome Atlas Research, 2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, 1061, 10.1038/nature07385 · DOI · Paper page
- N. Cancer Genome Atlas Research, 2011, Integrated genomic analyses of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166 · DOI · Paper page
- N. Cancer Genome Atlas Research, 2014, Comprehensive molecular characterization of urothelial bladder carcinoma, Nature, 507, 315, 10.1038/nature12965 · DOI
- N. Cancer Genome Atlas Research, 2017, Integrated genomic and molecular characterization of cervical cancer, Nature, 543, 378, 10.1038/nature21386 · DOI · Paper page
- Hoadley, 2014, Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin, Cell, 158, 929, 10.1016/j.cell.2014.06.049 · DOI · Paper page
- Liu, 2018, N. Cancer genome atlas research, H. Hu, an integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics, Cell, 173, 400, 10.1016/j.cell.2018.02.052 · DOI · Paper page
- Mejia-Pedroza, 2018, Pathway-based drug repositioning for breast Cancer Molecular subtypes, Front. Pharmacol., 9, 905, 10.3389/fphar.2018.00905 · DOI
- Lee, 2016, Drug repositioning for Cancer therapy based on large-scale drug-induced transcriptional signatures, PLoS One, 11, 10.1371/journal.pone.0150460 · DOI · Paper page
- Xu, 2018, Accurate drug repositioning through non-tissue-Specific core signatures from Cancer transcriptomes, Cell Rep., 25, 523, 10.1016/j.celrep.2018.09.031 · DOI
- Turanli, 2019, Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning, EBioMedicine, 42, 386, 10.1016/j.ebiom.2019.03.009 · DOI
- Yang, 2019, Novel drug candidate for the treatment of several softtissue sarcoma histologic subtypes: a computational method using survivalassociated gene signatures for drug repurposing, Oncol. Rep., 41, 2241
- Luo, 2009, Principles of cancer therapy: oncogene and non-oncogene addiction, Cell, 136, 823, 10.1016/j.cell.2009.02.024 · DOI · Paper page
- Pagliarini, 2015, Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure, EMBO Rep., 16, 280, 10.15252/embr.201439949 · DOI · Paper page
- Nussinov, 2016, A new view of ras isoforms in cancers, Cancer Res., 76, 18, 10.1158/0008-5472.CAN-15-1536 · DOI · Paper page
- Qian, 2005, In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis, Cancer Res., 65, 5045, 10.1158/0008-5472.CAN-04-3208 · DOI · Paper page
- Tsang, 2016, Functional annotation of rare gene aberration drivers of pancreatic cancer, Nat. Commun., 7, 10500, 10.1038/ncomms10500 · DOI · Paper page
- Vallejo, 2017, An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer, Nat. Commun., 8, 14294, 10.1038/ncomms14294 · DOI · Paper page
- Stelniec-Klotz, 2012, Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS, Mol. Syst. Biol., 8, 601, 10.1038/msb.2012.32 · DOI
- Singh, 2009, A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival, Cancer Cell, 15, 489, 10.1016/j.ccr.2009.03.022 · DOI · Paper page
- Brijwani, 2017, Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2, Sci. Rep., 7, 1502, 10.1038/s41598-017-01566-x · DOI
- Ntai, 2018, Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk, Proc. Natl. Acad. Sci. U. S. A., 115, 4140, 10.1073/pnas.1716122115 · DOI · Paper page
- Demory Beckler, 2013, Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS, Mol. Cell Proteomics, 12, 343, 10.1074/mcp.M112.022806 · DOI · Paper page
- Ye, 2016, Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface, Oncotarget, 7, 86948, 10.18632/oncotarget.13566 · DOI
- Brunelli, 2016, Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo, Sci. Rep., 6, 28398, 10.1038/srep28398 · DOI
- Charitou, 2019, Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRAS(G13D) mutation, Br. J. Cancer, 121, 37, 10.1038/s41416-019-0477-7 · DOI
- LaConti, 2015, Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma, BMC Genomics, 16, S1, 10.1186/1471-2164-16-S1-S1 · DOI
- Chen, 2018, Targeting oncogenic Myc as a strategy for cancer treatment, Signal Transduct. Target. Ther., 3, 5, 10.1038/s41392-018-0008-7 · DOI · Paper page
- Kalkat, 2017, MYC deregulation in primary human cancers, Genes (Basel), 8, 10.3390/genes8060151 · DOI · Paper page
- Whitfield, 2017, Strategies to inhibit myc and their clinical applicability, Front. Cell Dev. Biol., 5, 10, 10.3389/fcell.2017.00010 · DOI · Paper page
- Lopez, 2019, Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma, Nat. Commun., 10, 1459, 10.1038/s41467-019-08578-3 · DOI
- Horiuchi, 2012, MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition, J. Exp. Med., 209, 679, 10.1084/jem.20111512 · DOI · Paper page
- Wolfer, 2010, MYC regulation of a "poor-prognosis" metastatic cancer cell state, Proc Natl Acad Sci U S A, 107, 3698, 10.1073/pnas.0914203107 · DOI · Paper page
- Yang, 2017, A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: a systematic discovery (Target neuroblastoma ESC-like signature), Sci. Rep., 7, 41, 10.1038/s41598-017-00122-x · DOI
- Shachaf, 2008, Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance, Cancer Res., 68, 5132, 10.1158/0008-5472.CAN-07-6192 · DOI · Paper page
- Kalkat, 2018, MYC protein interactome profiling reveals functionally distinct regions that cooperate to drive tumorigenesis, Mol. Cell, 72, 836, 10.1016/j.molcel.2018.09.031 · DOI · Paper page
- Pan, 2009, Quantitative proteomics investigation of pancreatic intraepithelial neoplasia, Electrophoresis, 30, 1132, 10.1002/elps.200800752 · DOI
- Shiio, 2002, Quantitative proteomic analysis of Myc oncoprotein function, EMBO J., 21, 5088, 10.1093/emboj/cdf525 · DOI · Paper page
- Elkon, 2015, Myc coordinates transcription and translation to enhance transformation and suppress invasiveness, EMBO Rep., 16, 1723, 10.15252/embr.201540717 · DOI
- Tu, 2018, MYC interacts with the G9a histone methyltransferase to drive transcriptional repression and tumorigenesis, Cancer Cell, 34, 579, 10.1016/j.ccell.2018.09.001 · DOI
- Tarrado-Castellarnau, 2017, De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition, Mol. Syst. Biol., 13, 940, 10.15252/msb.20167321 · DOI
- Hall, 2016, Myc expression drives aberrant lipid metabolism in lung Cancer, Cancer Res., 76, 4608, 10.1158/0008-5472.CAN-15-3403 · DOI
- Satoh, 2017, Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC, Proc. Natl. Acad. Sci. U. S. A., 114, E7697, 10.1073/pnas.1710366114 · DOI · Paper page
- Camarda, 2016, Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer, Nat. Med., 22, 427, 10.1038/nm.4055 · DOI · Paper page
- Bott, 2015, Oncogenic myc induces expression of glutamine synthetase through promoter demethylation, Cell Metab., 22, 1068, 10.1016/j.cmet.2015.09.025 · DOI · Paper page
- Daugherty, 2007, Phospho-regulation of Beta-catenin adhesion and signaling functions, Physiology Bethesda, 22, 303, 10.1152/physiol.00020.2007 · DOI · Paper page
- Kahn, 2014, Can we safely target the WNT pathway?, Nat. Rev. Drug Discov., 13, 513, 10.1038/nrd4233 · DOI · Paper page
- Polakis, 2012, Drugging Wnt signalling in cancer, EMBO J., 31, 2737, 10.1038/emboj.2012.126 · DOI · Paper page
- Chen, 2010, Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry, J. Proteome Res., 9, 4215, 10.1021/pr1005197 · DOI
- Ewing, 2018, Multiproteomic and transcriptomic analysis of oncogenic beta-catenin molecular networks, J. Proteome Res., 17, 2216, 10.1021/acs.jproteome.8b00180 · DOI
- Vergara, 2017, Beta-catenin knockdown affects mitochondrial biogenesis and lipid metabolism in breast Cancer cells, Front. Physiol., 8, 544, 10.3389/fphys.2017.00544 · DOI · Paper page
- Voloshanenko, 2018, Beta-catenin-independent regulation of Wnt target genes by RoR2 and ATF2/ATF4 in colon cancer cells, Sci. Rep., 8, 3178, 10.1038/s41598-018-20641-5 · DOI
- Semaan, 2019, Proteomic screen with the proto-oncogene beta-catenin identifies interaction with Golgi coatomer complex I, Biochem. Biophys. Rep., 19
- Rosenbluh, 2016, Genetic and proteomic interrogation of lower confidence candidate genes reveals signaling networks in beta-catenin-Active cancers, Cell Syst., 3, 302, 10.1016/j.cels.2016.09.001 · DOI · Paper page
- Chang, 2015, Diverse targets of beta-catenin during the epithelial-mesenchymal transition define Cancer stem cells and predict disease relapse, Cancer Res., 75, 3398, 10.1158/0008-5472.CAN-14-3265 · DOI
- Nsengimana, 2018, Beta-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas, J. Clin. Invest., 128, 2048, 10.1172/JCI95351 · DOI · Paper page
- Wang, 2018, Targeting Wnt/beta-Catenin signaling for Cancer immunotherapy, Trends Pharmacol. Sci., 39, 648, 10.1016/j.tips.2018.03.008 · DOI · Paper page
- Bou-Hanna, 2015, Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis, Cancer Lett., 359, 211, 10.1016/j.canlet.2015.01.014 · DOI
- Duffy, 2017, Mutant p53 as a target for cancer treatment, Eur. J. Cancer, 83, 258, 10.1016/j.ejca.2017.06.023 · DOI · Paper page
- Liang, 2009, PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein, Int. J. Oncol., 35, 1015
- Zandi, 2011, PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53, Clin. Cancer Res., 17, 2830, 10.1158/1078-0432.CCR-10-3168 · DOI · Paper page
- Zhao, 2017, Molecularly targeted therapies for p53-mutant cancers, Cell. Mol. Life Sci., 74, 4171, 10.1007/s00018-017-2575-0 · DOI
- Pfefferle, 2016, Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers, Dis. Model. Mech., 9, 749
- Tanikawa, 2017, The transcriptional landscape of p53 signalling pathway, EBioMedicine, 20, 109, 10.1016/j.ebiom.2017.05.017 · DOI
- Arandkar, 2018, Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features, Proc Natl Acad Sci U S A, 115, 6410, 10.1073/pnas.1719076115 · DOI · Paper page
- Badal, 2017, Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation, JCI Insight, 2, 10.1172/jci.insight.92102 · DOI
- Sanchez, 2014, Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature, Nat. Commun., 5, 5812, 10.1038/ncomms6812 · DOI · Paper page
- Koifman, 2018, A mutant p53-Dependent embryonic stem cell gene signature is associated with augmented tumorigenesis of stem cells, Cancer Res., 78, 5833, 10.1158/0008-5472.CAN-18-0805 · DOI
- Taguchi, 2014, Proteomic signatures associated with p53 mutational status in lung adenocarcinoma, Proteomics, 14, 2750, 10.1002/pmic.201400378 · DOI
- Hunten, 2015, p53-Regulated Networks of Protein, mRNA, miRNA, and lncRNA Expression Revealed by Integrated Pulsed Stable Isotope Labeling With Amino Acids in Cell Culture (pSILAC) and Next Generation Sequencing (NGS) Analyses, Mol. Cell Proteomics, 14, 2609, 10.1074/mcp.M115.050237 · DOI · Paper page
- Novo, 2018, Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels, Nat. Commun., 9, 5069, 10.1038/s41467-018-07339-y · DOI · Paper page
- Andrysik, 2017, Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity, Genome Res., 27, 1645, 10.1101/gr.220533.117 · DOI · Paper page
- Lowman, 2019, M.B. Ishak Gabra, T.Q. tran, H. Li, M. Kong, p53 promotes Cancer cell adaptation to glutamine deprivation by upregulating Slc7a3 to increase arginine uptake, Cell Rep., 26, 3051, 10.1016/j.celrep.2019.02.037 · DOI · Paper page
- Green, 2006, p53 and metabolism: inside the TIGAR, Cell, 126, 30, 10.1016/j.cell.2006.06.032 · DOI · Paper page
- Kumar, 2018, Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers, Nat. Commun., 9, 3931, 10.1038/s41467-018-05805-1 · DOI
- Steck, 1997, Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers, Nat. Genet., 15, 356, 10.1038/ng0497-356 · DOI · Paper page
- Jiang, 2008, PI3K/PTEN signaling in tumorigenesis and angiogenesis, Biochim. Biophys. Acta, 1784, 150, 10.1016/j.bbapap.2007.09.008 · DOI · Paper page
- Lee, 2018, The functions and regulation of the PTEN tumour suppressor: new modes and prospects, Nat. Rev. Mol. Cell Biol., 19, 547, 10.1038/s41580-018-0015-0 · DOI · Paper page
- Zhang, 2010, PI(3)king apart PTEN’s role in cancer, Clin. Cancer Res., 16, 4325, 10.1158/1078-0432.CCR-09-2990 · DOI · Paper page
- Altinoglu, 2016, Intracellular delivery of the PTEN protein using cationic lipidoids for cancer therapy, Biomater. Sci., 4, 1773, 10.1039/C6BM00580B · DOI · Paper page
- Hopkins, 2013, A secreted PTEN phosphatase that enters cells to alter signaling and survival, Science, 341, 399, 10.1126/science.1234907 · DOI · Paper page
- Saito, 2003, Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo, Gene Ther., 10, 1961, 10.1038/sj.gt.3302100 · DOI
- Tomioka, 2008, Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation, Mol. Cancer Ther., 7, 1864, 10.1158/1535-7163.MCT-07-2198 · DOI
- Zhang, 2010, MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC), Clin. Chim. Acta, 411, 846, 10.1016/j.cca.2010.02.074 · DOI · Paper page
- Vidotto, 2018, Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer, Mol. Cytogenet., 11, 1, 10.1186/s13039-017-0348-y · DOI
- Jones, 2013, Comprehensive analysis of PTEN status in breast carcinomas, Int. J. Cancer, 133, 323, 10.1002/ijc.28021 · DOI
- Duan, 2015, PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype, Nat. Commun., 6, 10068, 10.1038/ncomms10068 · DOI · Paper page
- Peng, 2014, Genome-wide transcriptome profiling of homologous recombination DNA repair, Nat. Commun., 5, 3361, 10.1038/ncomms4361 · DOI · Paper page
- Mathur, 2017, PTEN regulates glutamine flux to pyrimidine synthesis and sensitivity to dihydroorotate dehydrogenase inhibition, Cancer Discov., 7, 380, 10.1158/2159-8290.CD-16-0612 · DOI · Paper page
- Garcia-Cao, 2012, Systemic elevation of PTEN induces a tumor-suppressive metabolic state, Cell, 149, 49, 10.1016/j.cell.2012.02.030 · DOI · Paper page
- Zhou, 2019, Effect of PTEN loss on metabolic reprogramming in prostate cancer cells, Oncol. Lett., 17, 2856
- Nevins, 2007, Mining gene expression profiles: expression signatures as cancer phenotypes, Nat. Rev. Genet., 8, 601, 10.1038/nrg2137 · DOI · Paper page
- Furge, 2007, Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling, Oncogene, 26, 1346, 10.1038/sj.onc.1210256 · DOI
- Bild, 2006, Oncogenic pathway signatures in human cancers as a guide to targeted therapies, Nature, 439, 353, 10.1038/nature04296 · DOI · Paper page
- Jeon, 2018, In silico drug combination discovery for personalized cancer therapy, BMC Syst. Biol., 12, 16, 10.1186/s12918-018-0546-1 · DOI
- Jerby-Arnon, 2014, Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality, Cell, 158, 1199, 10.1016/j.cell.2014.07.027 · DOI · Paper page
- Lee, 2018, Harnessing synthetic lethality to predict the response to cancer treatment, Nat. Commun., 9, 2546, 10.1038/s41467-018-04647-1 · DOI · Paper page
- Magen, 2019, Beyond synthetic lethality: charting the landscape of pairwise gene expression states associated with survival in Cancer, Cell Rep., 28, 938, 10.1016/j.celrep.2019.06.067 · DOI
- Preuer, 2018, DeepSynergy: predicting anti-cancer drug synergy with Deep Learning, Bioinformatics, 34, 1538, 10.1093/bioinformatics/btx806 · DOI · Paper page
- Sinha, 2017, Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data, Nat. Commun., 8, 15580, 10.1038/ncomms15580 · DOI
Cited by
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner, J., Wickman, E., DeRenzo, C., & Gottschalk, S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 380
Viceconti, M., Pappalardo, F., Rodriguez, B., Horner, M., Bischoff, J., & Musuamba Tshinanu, F. (2021) · Methods · doi:10.1016/j.ymeth.2020.01.011 · Cited by 361
“Predictive models developed using traditional frequentist statistics [23 – 25], as well as machine learning models [26 – 28], do not rely in general on prior knowledge; thus, they are not a ff ected by epistemic error.”
Method
Metadata
- Authors
- Mottini, C., Napolitano, F., Li, Z., Gao, X., & Cardone, L.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 68
- Pages
- 59-74
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2975915853
- Cited by
- 118
- References
- 48
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- National Cancer Institute
- King Abdullah University of Science and Technology (FCC/1/1976-18-01, FCC/1/1976-23-01, FCC/1/1976-25-01, FCC/1/1976-26-02, FCS/1/4102-02-01)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets. https://app.cochat.ai/papers/10.1016/j.semcancer.2019.09.023
- The paper
- Mottini, C., Napolitano, F., Li, Z., Gao, X., & Cardone, L. (2021). Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2019.09.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.